12 results about "Chimeric virus" patented technology

The application discloses a PEDV chimeric virus attenuation identification method based on reverse genetic operation and application of screening potential attenuated vaccine, and the PEDV chimeric virus CHM2013-SP BJ , CHM2013- BJ , CHM2013-SP BJ -ORF3 CHM , CHM2013-SP BJ -E CHM , CHM2013-SP BJ -M CHM , CHM2013-SP BJ -N CHM and CHM2013-(S+ORF3) BJ are constructed and rescued, loss-of-function test and gain-of-function test are carried out, and the attenuated chimeric virus CHM2013-SP BJ -ORF3 CHM and CHM2013-SP BJ -M CHM are obtained, and it is disclosed that the S gene of the PEDV variant BJ2011C promotes virus pathogenicity in cooperation with the ORF3, E and M genes, and the ORF3 gene is the most critical.

This invention belongs to the field of biomedical technology, specifically relating to a method for constructing a highly cell-adaptive PEDV GIIc recombinant chimeric virus. Specifically, this invention, based on the PEDV viral S protein determining PEDV's cell adaptability, innovatively elucidates that S2 is the key subunit determining its cell adaptability. On this basis, this invention proposes a scheme that can increase viral titer and thus reduce vaccine production costs when preparing candidate vaccine strains of circulating PEDV strains (especially GIIc). This involves retaining the S2 subunit of the highly cell-adaptive strain and replacing the S1 subunit of the highly cell-adaptive strain with the S1 subunit of the circulating strain, or replacing the S2 subunit of the circulating strain with the S2 subunit of the highly cell-adaptive strain. This scheme can both preserve the immunogenicity of the circulating strain and improve the efficiency of high-titer vaccine production.

The present invention relates to polynucleotides comprising a sequence of a live, infectious, attenuated Flavivirus wherein a nucleotide sequence encoding at least a part of a Filovirus glycoprotein is located at the intergenic region between the E and NS1 gene of said Flavivirus, such that a chimeric virus is expressed, characterised in that the encoded sequence C terminally of the E protein of said Flavivirus and N terminally of the signal peptide of the NS1 protein of said Flavivirus comprises in the following order: a further signal peptide of a Flavivirus NS1 protein, a filovirus glycoprotein wherein the N terminal signal peptide is absent, a TM domain of a flaviviral E protein.

The invention belongs to the technical field of genetic engineering, and particularly relates to a chimeric virus-like particle vaccine of feline coronavirus and feline panleucopenia virus and application of the chimeric virus-like particle vaccine. The invention provides chimeric virus-like particles of feline coronavirus and feline panleucopenia virus. The chimeric virus-like particles contain feline coronavirus type I S protein and feline panleucopenia virus VP2 protein. The invention also provides a preparation method and application of the chimeric virus-like particle. After the vaccine prepared from the chimeric virus-like particles is used for immunizing mice and cats, a high-titer antibody level can be generated, and the organism is stimulated to generate cellular immunity; the immunized cat can effectively resist invasion of cat coronavirus and cat panleucopenia virus. The chimeric virus-like particle has good immunogenicity and can be used for preventing and controlling cat infectious diseases.

The application discloses a bovine viral diarrhea virus chimeric virus expressing porcine circovirus type 3 capsid protein and a preparation method thereof. In the experiment, a gene sequence for encoding a porcine circovirus type 3 capsid protein and a His tag fused with the C terminal of the protein is inserted into different sites of a bovine viral diarrhea virus genome through a circular polymerase extension reaction, and the chimeric virus is prepared through virus rescue of the obtained circular DNA. The His tag sequence in the gene sequence and the bovine viral diarrhea virus genome are connected through a 2A peptide sequence, so as to realize the target of effectively releasing the antigen through the co-expression of the heterologous protein. The chimeric virus prepared by the application retains the infectivity and replication capacity of the parent virus, can stably replicate in cells and efficiently express the target antigen, and provides an efficient and flexible virus carrier platform for the research and development of a porcine circovirus type 3 vaccine.

A composition includes a contraceptive chimeric virus-like particle with an antigenic carrier domain and one or more antigenic regions from a sperm cell in the antigenic carrier domain, with the antigenic carrier domain including human papillomavirus L1 capsid protein and the antigenic regions including one or more structural elements of the Catsper ion channel complex. When administered to a patient, the contraceptive vaccine stimulates production of anti-sperm antibodies that, upon binding to a sperm cell, inhibit the sperm cell's motility and thus inhibit the ability of the sperm cell to fertilize an egg cell. The induced immunoinfertility of the composition can be reversed for brief or extended lengths of time by overdosing the patient with a reversal agent lacking the antigenic carrier domain but having a protein sequence substantially identical to that of the one or more antigenic regions to sequester the anti-sperm antibodies.

This disclosure describes a chimeric respiratory syncytial virus encoding a chimeric RSV and hMPV F protein and uses of the chimeric virus or components therein in a vaccine. In certain embodiments, this disclosure describes a live attenuated vaccine comprising an RSV backbone substituting the F proteins of RSV, for a chimeric RSV and hMPV F protein.

Provided herein are live attenuated viruses for protection against respiratory syncytial virus (RSV) and / or coronavirus Sars-CoV-2. The live attenuated chimeric virus strains utilize a master backbone based on a live attenuated influenza virus (LAIV), which includes a deletion of the viral virulence element, the NS1 (non-structural protein 1) (DeLNS1). These chimeric strains are engineered to express one or more antigens of RSV alone or in combination with Sars-CoV-2. The chimeric virus strain can protect a subject in need thereof against a challenge from any of RSV, Sars-CoV-2, influenza, or a combination thereof. This viral vector system offers an important strategy for developing highly attenuated and immunogenic live attenuated vaccines with the capacity to induce protective immunity against the three respiratory infections.

The present disclosure relates to a recombinant chimeric virus-like particle (cVLP) vaccine composition against rotavirus infection. The vaccine comprises a virus-like particle fragment including a hepatitis B core (HBc) protein functioning as an adjuvant, into which a heterologous immunogenic domain derived from the rotavirus VPS* protein is inserted within the major immunodominant region (MIR) of HBc. The construct is encoded by SEQ ID NO. 1, and expressed in a prokaryotic system. The cVLPVPS* vaccine composition of the present disclosure offers a non-replicating, protein-based alternative to live attenuated vaccines, and the platform may help address challenges related to safety, strain specificity, and antigen delivery.

The present invention relates to polynucleotides comprising a sequence of a live, infectious, attenuated Flavivirus wherein a nucleotide sequence encoding at least a part of a arenavirus glycoprotein protein is located at the intergenic region between the E and NS1 gene of said Flavivirus, such that a chimeric virus is expressed, characterised in that the encoded sequence C terminally of the E protein of said Flavivirus and N terminally of the signal peptide of the NS1 protein of said Flavivirus comprises in the following order: —a further signal peptide of a Flavivirus NS1 protein, —an arenavirus Glycoprotein protein lacking the N terminal signal sequence and the GP2 transmembrane domain, —a TM1 and TM2 domain of a flaviviral E protein.

The invention relates to the technical field of biological medicines, in particular to an optimized SARS-CoV-2 chimeric virus-like particle based on an influenza virus skeleton and an application of the optimized SARS-CoV-2 chimeric virus-like particle. The amino acid sequence of the spike protein of the virus-like particle comprises an extracellular domain amino acid sequence; the amino acid sequence of the extracellular domain has S-6P mutation (F817P, A892P, A899P, A942P, K986P and V987P) and Frelin restriction enzyme cutting site substitution (RRAR-GSAS). The optimization mode can maintain natural trimer conformation before S protein fusion and effectively improve the stability of the S protein, so that the dissociation phenomenon of the protein is effectively improved, and the influence of the dissociation phenomenon on effective epitopes is avoided. In order to improve the secretory expression efficiency of the VLPs, the protein expression is optimized by using a signal peptide derived from an insect cell-baculovirus expression system. The immunogenicity and immune protection efficacy of the vaccine can be effectively improved.

The invention relates to a vaccine, in particular to a chimeric virus-like particle vaccine based on an echovirus 30 type key epitope as well as a preparation method and application of the chimeric virus-like particle vaccine. The invention provides a method for screening antigen epitopes, which comprises the following steps: firstly, predicting the antigen epitope of capsid protein VP1 through bioinformatics analysis, and then screening epitopes which can be effectively combined with anti-VP1 complete sequence serum through enzyme-linked immunosorbent assay. Results of an enzyme-linked immunosorbent assay show that the expressed antigen epitope peptide E30-6 (SEQ ID NO: 2) can be strongly combined with E30 VP1 antiserum, so that one high-immunogenicity antigen epitope peptide is screened based on the complete sequence of the echovirus 30 VP1, which has important guiding significance for research and development of echovirus 30 vaccines. Besides, the HBc-E30-6 vaccine is designed and prepared based on the epitope, the HBc-E30-6 vaccine is high in purity and can be self-assembled into VLP nanoparticles, and more importantly, serum immunized by the vaccine can effectively neutralize the echovirus 30.